End-of-day quote
Shanghai S.E.
23:00:00 20/05/2024 BST
|
5-day change
|
1st Jan Change
|
30.81
CNY
|
-3.81%
|
|
-6.64%
|
-40.82%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,487
|
11,544
|
7,829
|
4,633
|
-
|
-
|
Enterprise Value (EV)
1 |
18,487
|
11,544
|
7,829
|
4,633
|
4,633
|
4,633
|
P/E ratio
|
84.6
x
|
58.3
x
|
64.3
x
|
27.1
x
|
18.6
x
|
13.6
x
|
Yield
|
-
|
-
|
0.29%
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.1
x
|
8.5
x
|
4.17
x
|
1.93
x
|
1.52
x
|
1.28
x
|
EV / Revenue
|
19.1
x
|
8.5
x
|
4.17
x
|
1.93
x
|
1.52
x
|
1.28
x
|
EV / EBITDA
|
-
|
45.2
x
|
31.8
x
|
14.9
x
|
11.8
x
|
8.79
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
10.1
x
|
5
x
|
3.16
x
|
1.57
x
|
1.45
x
|
1.47
x
|
Nbr of stocks (in thousands)
|
145,710
|
149,125
|
150,387
|
150,387
|
-
|
-
|
Reference price
2 |
126.9
|
77.41
|
52.06
|
30.81
|
30.81
|
30.81
|
Announcement Date
|
24/02/22
|
26/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
635.1
|
969.2
|
1,358
|
1,879
|
2,396
|
3,045
|
3,612
|
EBITDA
1 |
-
|
-
|
255.6
|
246.1
|
310.3
|
392.7
|
527
|
EBIT
1 |
-
|
209.8
|
196.6
|
134.3
|
158.3
|
234.3
|
379.5
|
Operating Margin
|
-
|
21.64%
|
14.47%
|
7.15%
|
6.61%
|
7.7%
|
10.51%
|
Earnings before Tax (EBT)
1 |
-
|
209.5
|
198.5
|
134.2
|
158.3
|
232.7
|
371.5
|
Net income
1 |
-
|
191
|
193.6
|
121.1
|
148.7
|
217.7
|
341
|
Net margin
|
-
|
19.7%
|
14.26%
|
6.45%
|
6.21%
|
7.15%
|
9.44%
|
EPS
2 |
1.173
|
1.500
|
1.329
|
0.8100
|
1.137
|
1.653
|
2.265
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.1500
|
-
|
-
|
-
|
Announcement Date
|
19/05/21
|
24/02/22
|
26/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
16.3%
|
9.9%
|
4.98%
|
5.71%
|
7.71%
|
10.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
3.09%
|
3.1%
|
4.1%
|
6.6%
|
Assets
1 |
-
|
-
|
-
|
3,923
|
4,796
|
5,309
|
5,167
|
Book Value Per Share
2 |
-
|
12.50
|
15.50
|
16.50
|
19.70
|
21.30
|
21.00
|
Cash Flow per Share
2 |
-
|
0.4000
|
-1.610
|
-0.4200
|
-0.0100
|
-0.5300
|
0.3300
|
Capex
1 |
-
|
-
|
581
|
259
|
192
|
135
|
105
|
Capex / Sales
|
-
|
-
|
42.75%
|
13.79%
|
8.01%
|
4.43%
|
2.91%
|
Announcement Date
|
19/05/21
|
24/02/22
|
26/02/23
|
23/02/24
|
-
|
-
|
-
|
Last Close Price
30.81
CNY Average target price
44
CNY Spread / Average Target +42.81% Consensus |
1st Jan change
|
Capi.
|
---|
| -40.82% | 666M | | -3.26% | 89.69B | | +2.50% | 41.34B | | -12.01% | 33.72B | | +62.74% | 26.11B | | -19.79% | 14.63B | | -8.58% | 12.84B | | -12.34% | 11.66B | | -43.92% | 11.52B | | +4.27% | 8.92B |
Biopharmaceuticals
|